What is new in atopic dermatitis/eczema?

Bibliography

• Ring J, Przybilla B, Ruzicka T. editor. Handbook of atopic eczema. 2nd edition, Springer, Berlin, Heidelberg, New York; 2006
   Google Scholar
• Leung DY. Atopic eczema: new insights and opportunities for therapeutic intervention. J Allergy Clin Immunol 2000;105:860-76
   PubMed Web of Science ®Google Scholar
• Ring J. Atopy: condition, disease or syndrome? In: Ring J, Przybilla B, Ruzicka T, editor. Handbook of atopic eczema. Springer; Berlin, Heidelberg, New York: 2006. p. 3
   Google Scholar
• Wise F, Sulzberger MB. Footnote on problem of eczema, neurodermatitis and lichenification. In: Wise F, Sulzberger MB, editors, The 1933 Year book of Dermatology and Syphilology. Year book publishers, Chicago; p. 38-9
   Google Scholar
• Hanifin JM. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980(Suppl 92):44-7
   Google Scholar
• Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party’s Diagnostic criteria for atopic dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994;131(3):397-405
   PubMed Web of Science ®Google Scholar
• Bos JD, van Leent EJ, Sillevis Smitt JH. The millennium criteria for the diagnosis of Atopic eczema. Exp Dermatol 1998;7:132-8
   PubMed Web of Science ®Google Scholar
• Darsow U, Vieluf D, Ring J. Evaluating the relevance of aeroallergen sensitation in atopic ezcema with the atopy patch test: a randomized, double-blind multicenter study. J Am Acad Dermatol 1999;40:187-93
   PubMed Web of Science ®Google Scholar
• Wüthrich B. Definition and diagnosis of intrinsic versus extrinsic atopic dermatitis. In: Bieber T, Leung DY, editors. Atopic dermatitis. Marcel Decker, New York; 2002. p. 1-20
   Google Scholar
• Ring J, Kramer U, Schafer T, Behrendt H. Why are allergies increasing? Curr Opin Immunol 2001;13:701-8
   PubMed Web of Science ®Google Scholar
• Williams HC, Strachan DP, Hay RJ. Childhood eczema: disease of the advantaged? BMJ 1994;308:1132-5
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Enomot T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science 1997;275:77-9
   PubMed Web of Science ®Google Scholar
• Yazdanbakhsh M, Kremser PG, van Ree R. Allergy, parasites and the hygiene hypothesis. Science 2002;296:490-4
   PubMed Web of Science ®Google Scholar
• Kramer U, Heinrich J, Wjst M, Wichmann HE. Age of entry to day nursery and allergy in later childhood. Lancet 1999;353:450-4
   PubMed Web of Science ®Google Scholar
• Riedler J, Braun-Fahrlander C, Eder W, et al. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;358:1129-33
   PubMed Web of Science ®Google Scholar
• Feary J, Britton J, Leonardi-Bee J. Atopy and current intestinal parasite infection: a systematic review and meta-analysis. Allergy 2011;66:569-78
   PubMed Web of Science ®Google Scholar
• Apfelbacher CJ, Diepgen TL, Schmitt J. Determinants of eczema: population-based cross-sectional study in Germany. Allergy 2011;66:206-13
   PubMed Web of Science ®Google Scholar
• Matricardi PM, Bonini S. High microbial turnover rate preventing atopy: a solution to inconsistencies impinging on the Hygiene hypothesis? Clin Exp Allergy 2000;30(11):1506-10
   PubMed Web of Science ®Google Scholar
• Schäfer T, Krämer U, Behrendt H, Ring J. Epidemiologie des atopischen Ekzems. Allergo J 2003;12:430-8
   Google Scholar
• Bieber T, de la Salle C, Wollenberg A, et al. Constitutive expression of the high affinity receptor for IgE (FcepsilonRa) on human Langerhans cells. J Exp Med 1992;175:1285-90
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Wen S, Bieber T. Langerhans´cells phenotyping: a new tool for differential diagnosis of inflammatory skin diseases. Lancet 1997;346:1626-7
   Web of Science ®Google Scholar
• Novak N. New insights into the mechanism and management of allergic diseases: atopic eczema. Allergy 2009;64:265-75
   PubMed Web of Science ®Google Scholar
• Homey B, Steinhoff M, Ruzicka T, Leung DY. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006;118:178-89
   PubMed Web of Science ®Google Scholar
• Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in Atopic eczema: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008;121:1337-43
   PubMed Web of Science ®Google Scholar
• Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic eczema with allergic sensitations. J Allergy Clin Immunol 2006;118:214-19
   PubMed Web of Science ®Google Scholar
• Proksch E, Folster-Holst R, Jensen JM. Skin barrier function, epidermal proliferation and differentiation in eczema. J Dermatol Sci 2006;43(3):159-69
   PubMed Web of Science ®Google Scholar
• Kezic S, O´Regan GM, Yau N, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. J Allergy Clin Immunol 2011;66:934-40
   Google Scholar
• De Benedetto A, Rafaels NM, Mc Girt LY, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011;41:272-81
   Google Scholar
• Gschwandtner M, Mildner M, Minz V. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013;68:37-47
   Google Scholar
• Guzik TJ, Bzowska M, Kasprowicz A, et al. Persistent skin colonization with Staphylococcus aureus in Atopic eczema: relationship to clinical and immunogical parameters. Clin Exp Allergy 2005;35:448-55
   PubMed Web of Science ®Google Scholar
• Breuer K, Werfel T, Kapp A. Staphylococcal exotoxins as trigger factors of atopic eczema. In: Ring J, Behrend H, editors. New trends in allergy V. Springer; Berlin, Heidelberg, New York: 2002. p. 145-56
   Google Scholar
• Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in Atopic eczema. N Engl J Med 2002;347:1151-60
   PubMed Web of Science ®Google Scholar
• Biedermann T. Dissecting the role of infections in atopic dermatitis. Acta Derm Venereol 2006;86:99-109
   PubMed Web of Science ®Google Scholar
• Ahmad-Nejad P, Mrabet-Dahbi S, Breuer K, et al. The toll-like receptor 2 R753Q polymorphism defines a subgroup of patients with atopic dermatitis having severe phenotype. J Allergy Clin Immunol 2004;113:565-7
   PubMed Web of Science ®Google Scholar
• Kong HH, Oh J, Deming C, et al. Temporal shifts in the skin mikrobiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850-9
   PubMed Web of Science ®Google Scholar
• Hong SW, Kim MR, Lee EY, et al. Extracellular vesicles derived from Staphylococcus aureus induce atopic dermatitis-like skin inflammation. Allergy 2011;66:351-9
   PubMed Web of Science ®Google Scholar
• Niebuhr M, Langnickel J, Draing C, et al. Dysregulation of toll-like-receptor-2 (TLR-2)-induced effects in monocytes from patients with atopic dermatitis: impact of the TLR-2 R753Q polymorphism. Allergy 2008;63:728-34
   PubMed Web of Science ®Google Scholar
• Kaesler S, Volz T, Skabytska Y, et al. Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4 mediated suppression of IL-10. J Allergy Clin Immunol 2014;134(1):92-9. e6
   PubMed Web of Science ®Google Scholar
• Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 2010;24:317-28
   PubMed Web of Science ®Google Scholar
• Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012;26:1045-60
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. American Academy of Allergy, Asthma and Immunology and the European Academy of Allergology and Clinical Immunology. Allergy 2006;61(8):969-87
   PubMed Web of Science ®Google Scholar
• Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30(10):861-81
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SJ, Kim D, Bang D. The effect of wet-wrap dressing on epidermal barrier in patients with atopic dermatitis. J Eur Acad Dermatol Venereol 2007;21(10):1360-8
   PubMed Web of Science ®Google Scholar
• Hoetzenecker W, Ecker R, Stingl G, et al. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic eczema. J Allergy Clin Immunol 2005;115:1276-83
   PubMed Web of Science ®Google Scholar
• Ring J, Abraham A, de Cuyper C, et al. Control of atopic eczema with pimecrolimus cream 1 % in pediatric patients with mild to moderate disease. J Am Acad Dermatol 2008;22:718-21
   Web of Science ®Google Scholar
• Reitamo S, Rustin M, Harper J, et al. 0,1% Tacrolimus ointment long-term follow-up study of atopic dermatitis therapy with 0,1% tacrolimus ointment in children an adult patients. Br J Dermatol 2008;159:942-51
   PubMed Web of Science ®Google Scholar
• Bieber T, Cork M, Ellis C, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 2005;211:77-8
   PubMed Web of Science ®Google Scholar
• Jensen JM, Pfeiffer S, Witt M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with Atopic eczema. J Allergy Clin Immunol 2009;14(3 Suppl 2):R19-28
   Google Scholar
• Jensen JM, Scherer A, Wanke C, et al. Gene expression is differently affected by pimecrolimus and betamehtasone in lesional skin of atopic dermatitis. Allergy 2012;67:413-23
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Reitamo S, Girolomonoi G, et al. Proactive treatment of atopic eczema in adults with 0,1 % tracrolimus ointment. Allergy 2008;63:742-50
   Web of Science ®Google Scholar
• Wollenberg A, Bieber T. Proactive therapy of atopic eczema– an emerging concept. Allergy 2009;64:276-8
   PubMed Web of Science ®Google Scholar
• Hong SP, Kim MJ, Jung MY, et al. Biopositive effects of low dose UVB on epidermis: coordinate upregulation of antimicrobial peptides and permeability barrier reinforcement. J Invest Dermatol 2008;128(12):2880-7
   PubMed Web of Science ®Google Scholar
• Gläser R, Navid F, Schuller W, et al. UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo. J Allergy Clin Immunol 2009;123(5):117-1123
   Google Scholar
• Schwarz T. The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisted. J Invest Dermatol 2009;130:49-54
   Web of Science ®Google Scholar
• Ohsawa Y, Hirasawa N. The antagonism of histamine H1 and H4 receptors ameliorates chronic allergic dermatitis via anti-pruritic and anti-inflammatory effects in NC/Nga mice. Allergy 2012;67:1014-22
   PubMed Web of Science ®Google Scholar
• Simon D, Bieber T. Systemic therapy for atopic dermatitis. Allergy 2014;69:46-55
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Feichtner K. Atopic dermatitis and skin allergies – update and outlook. Allergy 2013;68:1509-19
   PubMed Web of Science ®Google Scholar
• Brockow K, Grabenhorst P, Abeck D, et al. Effect of gentian violet, corticosteroid and tar preparations in staphylococcus-aureus- colonized atopic eczema. Dermatology 1999;199(3):231-6
   PubMed Web of Science ®Google Scholar
• Haeck IM, Knol MJ, Ten Berge O, et al. Enteric-coated mycophenenolate sodium versus cyclosporine as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011;64:1074-84
   PubMed Web of Science ®Google Scholar
• Murhpy LA, Atherton D. A retrospective evaluation of azathioprine in sever childhood atopic eczema, using thiopurine mehtyltransferase levels to exclude patients at hight risk of myelosuppression. Br J Dermatol 2002;147:324-30
   PubMed Web of Science ®Google Scholar
• Meggit SJ, Gray JC, Reynolds NJ. Azathoprine dosed by thiopurine methyltransferase activity for moderate-to-severe-atopic eczema: a double-blind, randomised controlled trial. Lancet 2006;367:839-46
   PubMed Web of Science ®Google Scholar
• Hoffjan S, Epplen JT. The genetics of Atopic eczema: recent findings and future options. J Mol Med 2005;83:682-92
   PubMed Web of Science ®Google Scholar
• Morar N, Cookson W, Harper J, Moffat M. Filaggrin mutations in children with severe atopic eczema. J Invest Dermatol 2007;127:1667-72
   PubMed Web of Science ®Google Scholar
• Walley AJ, Chavanas S, Moffat MF, et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:175-8
   PubMed Web of Science ®Google Scholar
• Foelster-Holst R, Stoll M, Koch WA, et al. Lack of asscociation of SPINK5 plymorphism with nonsyndromic atopic eczema in the population of Northern Germany. Br J Dermatol 2005;152:1365-7
   PubMed Web of Science ®Google Scholar
• Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009;8(12):1106-11
   PubMed Web of Science ®Google Scholar
• Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Euro Acad Dermatol Venerol 2006;54:821
   Google Scholar
• Belloni G, Pinelli S, Veraldi S. A randomised, double-blind, vehicle-controlled study to evaluate the efficacy and safety of MAS063D (Atopiclair) in the treatment of mild to moderate atopic dermatitis. Eur J Dermatol 2005;15:31-6
   PubMed Web of Science ®Google Scholar
• Werfel T, Breuer K, Rueff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61(2):202-5
   PubMed Web of Science ®Google Scholar
• Bussmann C, Maintz L, Hart J, et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007;37(9):1277-85
   PubMed Web of Science ®Google Scholar
• Cadario G, Gallucio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites hypersensitivity: a prospective pilot study. Curr Med Res Opin 2007;23:2503-6
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneuous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012;130:925-31
   PubMed Web of Science ®Google Scholar
• Novak N, Thaci D, Hoffman M, et al. Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract – a new therapeutic option for patients with atopic dermatitis. Int Arch Allergy Immunol 2011;155:252-6
   PubMed Web of Science ®Google Scholar
• Bae JM, Choi YY, Park CO, et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013;132:110-17
   PubMed Web of Science ®Google Scholar
• Grahovac M, Molin S, Prinz JC, et al. Treatment of atopic eczema with oral alitretinoin. Br J Dermatol 2010;162:217-18
   PubMed Web of Science ®Google Scholar
• Ogden NS, Biolory L. Probiotics, a complementary approach in the treatment and prevention of pediatric atopic disease. Curr Opin Allergy Clin Immunol 2005;5(2):179-84
   PubMed Web of Science ®Google Scholar
• Arkwrite PD, David TJ. Eat dirt-the hypothesis of atopic diseases. In: David TJ, editor, Recent advances in Paediatrics 21. Royal Society of Medicine Press Ltd, London; 2004. p. 199-215
   Google Scholar
• Kalliomaki M, Salminen S, Arvillommi H, et al. Probiotics in primary prevention of atopic disease. A randomized placebo-controlled trial. Lancet 2001;357:1076-9
   PubMed Web of Science ®Google Scholar
• Boyle RJ, Ismail IH, Kivivuori S, et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy 2011;66:509-16
   PubMed Web of Science ®Google Scholar
• Gueniche A, Knaudt B, Schuck E, et al. Effects of nonpathogenic gram-negative bacterium Vitreoscilla filimoris lysate on atopic dermatitis: a prospective, randomized, double-blind, placebo-controlled clinical study. Br J Dermatol 2008;159:1357-63
   PubMed Web of Science ®Google Scholar
• Volz T, Skabytska Y, Guenova E, et al. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J Invest Dermatol 2014;134:96-104
   PubMed Web of Science ®Google Scholar
• Volz T, Biedermann T. [Outside-in. Probiotic topical agents]. Hautarzt 2009;60(10):795-801
   PubMedGoogle Scholar
• Paul C, Lahfa M, Bachelez H, et al. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic eczema. Br J Dermatol 2002;147(3):518-22
   PubMed Web of Science ®Google Scholar
• Jolles S, Sewell C, Webster D, et al. Adjunctive high-dose intravenous immunoglobulin treatment for resistant Atopic eczema: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol 2003;83(6):433-7
   PubMed Web of Science ®Google Scholar
• Capella GL, Frigerio E, Altomar G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic eczema of adults. Eur J Dermatol 2001;11(3):209-13
   PubMed Web of Science ®Google Scholar
• Veien NK, Busch-Sorensen M, Stausbol-Gron B. Montelukast treatment of moderate to severe atopic eczema in adults: a randomized, double-blind, placebo controlled trial. J Am Acad Dermatol 2005;53:147-9
   PubMed Web of Science ®Google Scholar
• Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:1223-5
   PubMed Web of Science ®Google Scholar
• Andres C, Belloni B, Mempel M, Ring J. Omalizumab for patients with severe and therapy-refractory atopic eczema? Curr Allergy Asthma Rep 2008;8:179-80
   PubMed Web of Science ®Google Scholar
• Hotze M, Baurecht H, Rodriguez F, et al. Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filagrin status and higher serum levesl of phosphadidylcholines. Allergy 2014;69:132-5
   PubMed Web of Science ®Google Scholar
• Toledo F, Silvestre JF, Munoz C. Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis. Report of four cases. J Eur Acad Dermatol Venereol 2012;26:1325-7
   PubMed Web of Science ®Google Scholar
• Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME. Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 2013;23:190-6
   PubMed Web of Science ®Google Scholar
• Simon D, Wittwer J, Kostylina G, et al. Alefacept (lymphocyte function associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423-4
   PubMed Web of Science ®Google Scholar
• Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic eczema. J Allergy Clin Immunol 2008;122:423-4
   PubMed Web of Science ®Google Scholar
• Jacobi A, Antoni C, Manger B, et al. Infliximab in the treatment of moderate to severe Atopic eczema. J Am Acad Dermatol 2005;53:522-8
   Web of Science ®Google Scholar
• Ruiz Villaverde R, Galan-Gutierrez M. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr 2012;103:743-6
   PubMedGoogle Scholar
• Schmidt-Weber CB, In Ring J, Darsow U, Behrendt H. editor. New trends in allergy and atopic eczema. Volume 96 Karger, Basel; 2012; p. 120-5
   Google Scholar
• Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol 2000;105:1063-70
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble Il-4 receptor for the treatment of adults with asthma. J Allergy clin Immunol 2001;107:963-70
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 2007;370:1422-31
   PubMed Web of Science ®Google Scholar
• Hamilton J, Suarez-Farinas M, Kostic A, et al. Blocking IL-4Ralpha with dupilumab (REGN668/SAR231893) rapidly suppresses major pathogenic pathways in severe atopic dermatitis. Poster, Abstract p 1048
   Google Scholar
• Hamilton J, Beck LA, Ren H. Biomarkers elevated in atopic dermatitis (AD) are reduced by therapeutic blockade of IL-4 receptor alpha (IL-4alpha) signalling with dupilumab in patients with moderate-to-severe AD. Poster Abstract p 1042
   Google Scholar
• Yosipovitch G, Mayo M, Hamilton J. IL-4R alpha mAb dupilumab (REGN668/SAR231893) for the treatment of severe atopic dermatitis itch. Presented at International Investigative Dermatology; 8 – 11 May 2013; Edinburgh, Scotland
   Google Scholar
• Ploetz SG, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003;349(24):2334-9
   PubMed Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of Atopic eczema. Allergy 2005;60:693-6
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008;358:1215-28
   PubMed Web of Science ®Google Scholar
• Simon D, Hösli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy clin Immunol 2008;121:122-8
   PubMed Web of Science ®Google Scholar
• Imai T, Nagira M, Takagi S, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999;11:81-8
   PubMed Web of Science ®Google Scholar
• Wakugawa M, Nakamura K, Kainuma T, Tamaki K. CC chemokine receptor 4 as a possible target for therapy of atopic dermatitis. Drug News Perspect 2002;15(3):175
   PubMed Web of Science ®Google Scholar
• Schacke H, Hennekes H, Schottelius A, et al. SEGRAs: a novel class of anti-inflammatory compounds. Ernst Schering Res Found Workshop 2002(40):375-1
   Google Scholar
• Schacke H, Zollner TM, Docke WD, et al. Characterization of ZK 245186, a novel, selective glucocorticoid receptor agonist fort he topical treatment of inflammatory skin diseases. Br J Pharmacol 2009;158(4):1088-103
   PubMed Web of Science ®Google Scholar
• Clinical trials gov. NCT00944632 Dose escalation of different Concentrations of ZK245186 in atopic dermatitis. 2009. Available from: http://clinicaltrials.gov/show/NCT00944632 [Last accessed 19 February 2014]
   Google Scholar
• Sonkoly E, Muller A, Lauerma A, et al. IL-31: a new link between T-cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117(2):411-17
   PubMed Web of Science ®Google Scholar
• Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin immunol 2006;117:418-25
   PubMed Web of Science ®Google Scholar
• Schulz F, Marenholz I, Fölster-Holst R, et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 2007;120:1097-102
   PubMed Web of Science ®Google Scholar
• Clinical trials gov. NC01614756 A two part, phase 1, single-dose study of anti-31 mAb (Anti-Interleukin 31 monoclonal antibody); in healthy subjects and adults with atopic dermatitis. 2012. Available from: http://clinicaltrials.gov/show/NCT01614756 [Last accessed 11 August 2014]
   Google Scholar